Eli Lilly and Company: Beat — EPS $7.48, Revenue $24.4B
Earnings BeatQ3 2026 · Pre-market
Did Eli Lilly and Company (LLY) beat earnings today?
Yes, Eli Lilly and Company (LLY) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+13.16% surprise
$7.48Actual
Expected: $6.61
vs. year ago +7.0%
Total Revenue+7.86% surprise
$24.4BActual
Expected: $22.62B
vs. year ago +39.0%
Released Oct 29 · 6:45 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $24.40B | $17.60B | +39.0% |
| Revenue detail — reported lines | |||
| └─Mounjaro | $10.72B | $6.51B | +65.0% |
| └─Zepbound | $5.35B | $3.59B | +49.0% |
| └─Jaypirca | $228.00M | $143.00M | +59.0% |
| └─Ebglyss | $202.00M | $127.00M | +59.0% |
| └─Kisunla | $193.00M | $70.00M | +175.0% |
| └─Omvoh | $114.00M | $65.00M | +76.0% |
| └─Foundayo | $184.00M | - | - |
| └─Inluriyo | $73.00M | - | - |
| Net income - Reported | $6.45B | $5.58B | +16.0% |
| Net income - Non-GAAP | $6.68B | $6.31B | +6.0% |
| Earnings per share - Reported | $7.22 | $6.21 | +16.0% |
| Earnings per share - Non-GAAP | $7.48 | $7.02 | +7.0% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Outlook |
|---|---|---|
| Revenue | — | $91 to $92 billion (prev. $85 to $87 billion) |
| Performance Margin | — | 52.0% to 52.5% (prev. 49.0% to 50.5%) |
| Earnings per Share | — | $35.00 to $36.00 (prev. $35.50 to $36.50) |
| Shares outstanding | — | approximately 894 million |
| Euro | — | 1.13 |
| Yen | — | 157 |
| Yuan | — | 6.7 |
Business Highlights
- ➤U.S. FDA approved Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes.
- ➤U.S. FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes.
- ➤U.S. FDA approved Inluriyo with Verzenio for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
- ➤U.S. FDA expanded Jaypirca for adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- ➤Retatrutide showed positive topline Phase 3 results versus Ozempic 2 mg in type 2 diabetes.
- ➤EloraTZP Phase 2 results support Phase 3 trials beginning in Q4 2026.
- ➤Completed AtaiBeckley acquisition to advance treatment-resistant depression and mental health therapies.
- ➤Completed Merida Biosciences acquisition after quarter-end for autoimmune and allergic disease treatments.
- ➤Broke ground in Richmond to expand U.S. manufacturing of next-generation cancer medicines.
- ➤Broke ground in Houston, one of ten U.S. manufacturing sites announced since 2020.
- ➤Launched Lilly Change the Course Commitment to address diabetes and obesity treatment gaps in LMICs.
- ➤Named Ilya Yuffa president of Lilly Global Markets following Patrik Jonsson's planned retirement.
Management Commentary
David A. Ricks, Lilly chair and CEO
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia. Lilly is executing well across the value chain, and our potential for impact on human health continues to expand.”